Latest news with #risk
Bloomberg
4 hours ago
- Business
- Bloomberg
How to Keep Your CEO Off the Jumbotron
Opinion Why do executives, like the Astronomer CEO, keep taking needless risks? Bloomberg Opinion columnist Beth Kowitt knows a lot — maybe too much — about their bad behavior. (Source: Bloomberg)
Telegraph
a day ago
- Automotive
- Telegraph
Mrs, Miss or Ms? The tiny tweaks that could make your car insurance cheaper
When you're looking for a car insurance policy, you might think that the price only depends on what kind of car you have and how much you drive it. While both of those factors have a bearing on the policy prices you're quoted, the truth is that insurance companies take in the minutiae of all of your personal details when weighing up your level of risk – and, therefore, how much you're charged to cover it. There are some things you can't do anything about, such as your age. However, there are some tweaks you can make that can bring down your policy cost. The key when weighing up whether to change certain details is that they must still be true. If any of the information you provide is inaccurate, or you have lied in any way, you won't be covered if you make a claim. James Daley, MD at consumer group, Fairer Finance, also warned: 'There are lots of little ways you can bring down your car insurance premium – but you need to be careful experimenting with your answers on comparison sites, as you'll quickly get flagged as a fraud risk.' Here, Telegraph Money explains some of the tweaks you can make when searching for car insurance to reduce the cost – from altering your job title to adjusting your mileage. Consider your title Rethink your profession Think about where you park Alter your annual mileage Renew at the right time Consider your title The title used before your name can affect your car insurance quote. Data obtained by Which? shows that drivers using the title 'Mr' faced the highest average premium at £1,695, compared with £1,331 for 'Miss', £863 for 'Mrs' and £720 for 'Ms'. Insurers can no longer use a customer's gender to set prices. However, titles can indirectly reflect underlying risk factors, such as age and driving experience. Switching from 'Miss' to 'Ms', for example, may be worth checking when searching for a new quote – but this change alone is unlikely to result in a cheaper deal. Rethink your profession Insurers rely on claims data to assess which occupations are more likely to make a claim. If your job falls into a higher-risk category, you'll typically pay more for your car insurance. Analysis by Quotezone shows that healthcare assistants and warehouse workers face some of the highest premiums, at more than £1,000 a year. By comparison, nurses (£668.23), administration assistants (£663.49) and HGV drivers (£556.31) enjoy the cheapest premiums. You don't need to go through a career change if your occupation is at the higher end of the scale – instead, it's worth exploring whether you could describe your job in a different way when you're reviewing quotes, according to Greg Wilson, from Quotezone. This is a legitimate option if the alternative description still accurately explains what you do. 'As long as the description remains accurate and honest, variations in an individual's job title could help bring the cost down,' said Mr Wilson. For example, instead of describing yourself as a 'healthcare assistant', try changing it to 'care assistant' or 'care worker' to see if it lowers the cost. Similarly, if you're retired it can be cheaper to make sure you're described as such, rather than 'unemployed'. Think about where you park According to the RAC, wherever you describe as your overnight parking location at the time of applying for an insurance quote, or renewal, will be assumed as where your car is parked the majority of the time. Policy costs tend to reduce the more secure the parking location is – but, of course, it needs to reflect where your car is genuinely parked most of the time. RAC says that for insurance purposes, a 'driveway' can include asphalt, concrete, gravel or grass anywhere outdoors – but somewhere on your property. On-road parking describes a vehicle being parked at the side of the road near where you live, but not necessarily directly outside your property. To describe your car as being parked in a locked garage, this must be an enclosure on your property that is actually locked and requires a key to open it. It may sound obvious, but it's important to make sure the description is accurate – if you make a claim and your car is not parked where you described it, your claim could be invalidated. Alter your annual mileage If you've over-estimated the amount of driving you're going to be doing over the next year, you could be landing yourself with a needlessly expensive policy. This is down to the theory that driving fewer miles can reduce your risk of an accident, which is why lower mileage often leads to cheaper car insurance. But it's not always that simple. Research from Compare the Market found that the cheapest average premiums were for drivers covering between 11,000 and 11,999 miles a year, at £511. By comparison, more occasional drivers covering 10,000 to 10,999 miles paid more on average, at around £645. For this reason, it's worth testing a few realistic mileage brackets when comparing quotes. Just remember that your final figure must still be accurate. Exceeding the amount you've specified can invalidate your cover, and your insurer won't pay out in the event of a claim. Renew at the right time
Associated Press
a day ago
- Business
- Associated Press
Regnology to Acquire Wolters Kluwer's Finance, Risk & Regulatory Reporting Business Unit (FRR)
FRANKFURT, Germany--(BUSINESS WIRE)--Jul 21, 2025-- Regnology, a leading software provider with a focus on regulatory reporting solutions, today announced it has entered into a definitive agreement to acquire Wolters Kluwer's Finance, Risk & Regulatory Reporting (FRR) unit. The proposed acquisition represents a strategic step in Regnology's ambition to deliver regulatory intelligence at scale—bringing together complementary capabilities across finance, risk, and regulatory reporting. It also expands Regnology's presence in key markets and strengthens its ability to support financial institutions with granular data, jurisdiction-specific requirements, and cross-border compliance. Rob Mackay, CEO of Regnology, said: 'FRR brings additional expertise and reach that will enhance our ability to serve clients globally. We look forward to supporting clients with a unified platform that helps them modernize their infrastructure, navigate Basel IV, and prepare for the future of regulatory reporting.' Lisa Nelson, CEO of Wolters Kluwer Financial & Corporate Compliance, said: 'We are proud of the accomplishments of our Finance, Risk, and Regulatory Reporting teams. Regnology is strategically aligned to build on FRR's strengths, and we are confident that they are joining an organization that is well-positioned to continue serving customers with excellence while opening new growth opportunities for employees.' Fredrik Näslund, Partner, Nordic Capital Advisors commented: 'This agreement reflects Regnology's continued momentum and innovation in the regulatory technology space. It positions the company to deliver even greater value to financial institutions worldwide. Nordic Capital is truly excited about Regnology's continued journey.' Clients will benefit from a unified platform that combines Regnology's cloud-first architecture with FRR's established capabilities, offering scalable solutions for both heritage and cloud-ready environments. The transaction is expected to close in the coming months, subject to regulatory approvals, applicable employee requirements and customary conditions. View source version on CONTACT: Mireille Adebiyi – Chief Marketing Officer Email:[email protected] KEYWORD: GERMANY EUROPE INDUSTRY KEYWORD: PROFESSIONAL SERVICES DATA MANAGEMENT TECHNOLOGY SOFTWARE FINANCE FINTECH BANKING SOURCE: Regnology Copyright Business Wire 2025. PUB: 07/21/2025 02:00 AM/DISC: 07/21/2025 02:01 AM
Washington Post
4 days ago
- Climate
- Washington Post
Where there's risk of flooding across the U.S. this weekend
It's been a summer full of flooding — and there's more risk ahead for areas across the country from Friday through the weekend. About 20 million people are under flood watches Friday in two zones. One runs from Kentucky through most of West Virginia and Virginia. Another includes southern Louisiana and coastal Mississippi. Flooding is also anticipated elsewhere, but generally in more scattered fashion. Additional zones in the West and the Midwest are also under threat.
Yahoo
5 days ago
- Business
- Yahoo
Abbott Laboratories (NYSE:ABT) Has A Rock Solid Balance Sheet
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' When we think about how risky a company is, we always like to look at its use of debt, since debt overload can lead to ruin. Importantly, Abbott Laboratories (NYSE:ABT) does carry debt. But the real question is whether this debt is making the company risky. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. When Is Debt A Problem? Debt assists a business until the business has trouble paying it off, either with new capital or with free cash flow. If things get really bad, the lenders can take control of the business. However, a more common (but still painful) scenario is that it has to raise new equity capital at a low price, thus permanently diluting shareholders. Having said that, the most common situation is where a company manages its debt reasonably well - and to its own advantage. When we think about a company's use of debt, we first look at cash and debt together. What Is Abbott Laboratories's Debt? The image below, which you can click on for greater detail, shows that Abbott Laboratories had debt of US$13.3b at the end of March 2025, a reduction from US$14.7b over a year. However, because it has a cash reserve of US$6.84b, its net debt is less, at about US$6.45b. How Strong Is Abbott Laboratories' Balance Sheet? Zooming in on the latest balance sheet data, we can see that Abbott Laboratories had liabilities of US$13.0b due within 12 months and liabilities of US$19.4b due beyond that. On the other hand, it had cash of US$6.84b and US$7.33b worth of receivables due within a year. So it has liabilities totalling US$18.2b more than its cash and near-term receivables, combined. Since publicly traded Abbott Laboratories shares are worth a very impressive total of US$229.2b, it seems unlikely that this level of liabilities would be a major threat. But there are sufficient liabilities that we would certainly recommend shareholders continue to monitor the balance sheet, going forward. See our latest analysis for Abbott Laboratories We use two main ratios to inform us about debt levels relative to earnings. The first is net debt divided by earnings before interest, tax, depreciation, and amortization (EBITDA), while the second is how many times its earnings before interest and tax (EBIT) covers its interest expense (or its interest cover, for short). The advantage of this approach is that we take into account both the absolute quantum of debt (with net debt to EBITDA) and the actual interest expenses associated with that debt (with its interest cover ratio). Abbott Laboratories has a low net debt to EBITDA ratio of only 0.58. And its EBIT easily covers its interest expense, being 38.7 times the size. So you could argue it is no more threatened by its debt than an elephant is by a mouse. Also good is that Abbott Laboratories grew its EBIT at 10% over the last year, further increasing its ability to manage debt. When analysing debt levels, the balance sheet is the obvious place to start. But it is future earnings, more than anything, that will determine Abbott Laboratories's ability to maintain a healthy balance sheet going forward. So if you're focused on the future you can check out this free report showing analyst profit forecasts. Finally, a company can only pay off debt with cold hard cash, not accounting profits. So the logical step is to look at the proportion of that EBIT that is matched by actual free cash flow. Over the last three years, Abbott Laboratories recorded free cash flow worth a fulsome 81% of its EBIT, which is stronger than we'd usually expect. That puts it in a very strong position to pay down debt. Our View Abbott Laboratories's interest cover suggests it can handle its debt as easily as Cristiano Ronaldo could score a goal against an under 14's goalkeeper. And that's just the beginning of the good news since its conversion of EBIT to free cash flow is also very heartening. We would also note that Medical Equipment industry companies like Abbott Laboratories commonly do use debt without problems. Considering this range of factors, it seems to us that Abbott Laboratories is quite prudent with its debt, and the risks seem well managed. So the balance sheet looks pretty healthy, to us. There's no doubt that we learn most about debt from the balance sheet. But ultimately, every company can contain risks that exist outside of the balance sheet. We've identified 1 warning sign with Abbott Laboratories , and understanding them should be part of your investment process. Of course, if you're the type of investor who prefers buying stocks without the burden of debt, then don't hesitate to discover our exclusive list of net cash growth stocks, today. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
